Drug name - Zynrelef Kit
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9592227 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
| US9913909 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
| US11253504 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
| US10398686 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
| US9744163 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
| US10098957 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
| US10632199 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
| US10898575 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
| US11083797 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
| US10980886 | HERON THERAPS INC | Compositions of a polyorthoester and an organic acid excipient |
Apr, 2035
(12 years from now) | |
| US9694079 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
| US9801945 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
| US10213510 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
| US11083730 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient
Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarticular instillation
Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) | SOLUTION, EXTENDED RELEASE;PERIARTICULAR | Prescription |
| 200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) | SOLUTION, EXTENDED RELEASE;PERIARTICULAR | Prescription |
| 300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML) | SOLUTION, EXTENDED RELEASE;PERIARTICULAR | Prescription |
| 400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) | SOLUTION, EXTENDED RELEASE;PERIARTICULAR | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.